{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"10"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"1"}]}],"title":"Baseline ADA Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"18"},{"groupId":"OG013","value":"19"},{"groupId":"OG014","value":"16"},{"groupId":"OG015","value":"7"}]}],"title":"ADA Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"0"}]}],"title":"ADA Positive [Persistent Positive (PP)]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"9"},{"groupId":"OG015","value":"1"}]}],"title":"ADA Positive [Not PP-Last Sample Positive]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"12"},{"groupId":"OG013","value":"15"},{"groupId":"OG014","value":"4"},{"groupId":"OG015","value":"6"}]}],"title":"ADA Positive [Other Positive]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"}]}],"title":"Neutralizing Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"35"},{"groupId":"OG013","value":"35"},{"groupId":"OG014","value":"28"},{"groupId":"OG015","value":"43"}]}],"title":"ADA Negative"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"53"},{"groupId":"OG013","value":"54"},{"groupId":"OG014","value":"44"},{"groupId":"OG015","value":"50"}],"units":"Participants"}],"description":"Baseline ADA Positive: Participant with baseline ADA-positive sample ADA Positive: Participant with at least one ADA-positive sample relative to baseline Persistent Positive (PP): ADA-positive sample at 2 or more consecutive timepoints Not PP-Last Sample Positive: Not persistent but with ADA-positive sample at the last sampling timepoint Other Positive: Not persistent but some ADA-positive samples with the last sample being negative ADA Negative: Participant with no ADA-positive sample after initiation of treatment","groups":[{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.1 mg/kg every 2 weeks","id":"OG000","title":"Cohort 1 Uninfected HCC: Treatment 1"},{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.3 mg/kg every 2 weeks","id":"OG001","title":"Cohort 1 Uninfected HCC: Treatment 2"},{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 1 mg/kg every 2 weeks","id":"OG002","title":"Cohort 1 Uninfected HCC: Treatment 3"},{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 3 mg/kg every 2 weeks","id":"OG003","title":"Cohort 1 Uninfected HCC: Treatment 4"},{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 10 mg/kg every 2 weeks","id":"OG004","title":"Cohort 1 Uninfected HCC: Treatment 5"},{"description":"Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 0.3 mg/kg every 2 weeks","id":"OG005","title":"Cohort 1 HCV Infected: Treatment 6"},{"description":"Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 1 mg/kg every 2 weeks","id":"OG006","title":"Cohort 1 HCV Infected: Treatment 7"},{"description":"Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG007","title":"Cohort 1 HCV Infected: Treatment 8"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.1 mg/kg every 2 weeks","id":"OG008","title":"Cohort 1 HBV Infected: Treatment 9"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.3 mg/kg every 2 weeks","id":"OG009","title":"Cohort 1 HBV Infected: Treatment 10"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 1 mg/kg every 2 weeks","id":"OG010","title":"Cohort 1 HBV Infected: Treatment 11"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG011","title":"Cohort 1 HBV Infected: Treatment 12"},{"description":"Dose Expansion: Uninfected hepatocellular carcinoma (HCC) participants who are sorafenib naive/intolerant received nivolumab 3 mg/kg every 2 weeks","id":"OG012","title":"Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1"},{"description":"Dose Expansion: Uninfected hepatocellular carcinoma (HCC) participants who are sorafenib progressors received nivolumab 3 mg/kg every 2 weeks","id":"OG013","title":"Cohort 2 Uninfected Sorafenib Progressors: Treatment 2"},{"description":"Dose Expansion: Hepatitis C (HCV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG014","title":"Cohort 2 HCV Infected: Treatment 3"},{"description":"Dose Expansion: Hepatitis B (HBV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG015","title":"Cohort 2 HBV Infected: Treatment 4"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants in Cohort 1 and 2 with baseline and at least 1 post-baseline assessment. Pre-specified to be reported for Cohort 1 and 2 only.","reportingStatus":"POSTED","timeFrame":"From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)","title":"Number of Participants With Anti-drug Antibodies (ADA)","type":"SECONDARY","unitOfMeasure":"Participants"}